Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
European Wax Center Q3 2025 Earnings Call - Building Foundations with Stable Core and Data-Driven Transformation
European Wax Center reported steady progress in Q3 2025 with system-wide sales reaching $238.2 million and a slight 20 basis points increase in same-store sales, reflecting a stable core customer base...
- Q3 system-wide sales were $238.2 million, down 0.8% year-over-year mainly due to closed centers.
- Same-store sales grew modestly by 20 basis points, signaling a stable core business.
- Adjusted EBITDA rose 9.6% to $20.2 million, with margin improvement to 37.2%.
- +13 more takeaways
Sanara MedTech Q3 2025 Earnings Call - Strategic Shift to Core Surgical Business Fuels 22% Revenue Growth
Sanara MedTech’s third quarter 2025 earnings report marks a pivotal strategic shift, as the newly appointed CEO Seth Yon confirms the discontinuation of the Tissue Health Plus (THP) segment after an e...
- Seth Yon appointed Sanara’s President and CEO as of September 15, bringing seven years of internal commercial leadership experience to the top role.
- The company announced discontinuation of Tissue Health Plus (THP) operations after failing to find a partner to scale or monetize the business, signaling a strategic retreat from this segment.
- THP cash investment in H2 2025 expected between $5.5 million and $6.5 million, with no material cash spend anticipated post-2025.
- +10 more takeaways
Acurx Pharmaceuticals 3Q 2025 Earnings Call - Progress on Microbiome-Sparing Antibiotic Class and NASDAQ Compliance Achieved
Acurx Pharmaceuticals reported financial results for Q3 2025 while highlighting key operational milestones including a 1-for-20 reverse stock split that restored NASDAQ listing compliance. The company...
- Completed a 1-for-20 reverse stock split in August 2025, regaining NASDAQ minimum bid price compliance and meeting stockholder equity requirements to maintain listing.
- Received new Australian patent approval for DNA polymerase 3C inhibitors, adding to existing US, Israeli, Japanese, Indian patents and strengthening global IP coverage.
- Raised approximately $1.7 million from an equity line of credit during Q3 and an additional $1.4 million post-quarter through warrant exercises, ending with $5.9 million cash plus recent proceeds.
- +9 more takeaways
Acumen Pharmaceuticals Q3 2025 Earnings Call - Advancing Phase 2 Alzheimer's Trial with Strategic BBB Tech Collaboration
Acumen Pharmaceuticals reported solid progress in its phase two ALTITUDE-AD trial targeting synaptotoxic A-beta oligomers in Alzheimer's disease, with first participants moving into an open-label exte...
- ALTITUDE-AD phase two trial for sabirnetug, targeting toxic A-beta oligomers in Alzheimer's, is progressing steadily with 542 participants enrolled.
- First patients are entering the open-label extension (OLE), receiving 35 mg/kg sabirnetug every 4 weeks for up to 52 weeks to collect long-term safety and efficacy data.
- Top-line results for ALTITUDE-AD, including efficacy and safety, are expected in late 2026.
- +7 more takeaways
Katapult Holdings Q3 2025 Earnings Call - Accelerated Application Growth Drives Expanding Customer Base and Positive Adjusted EBITDA
Katapult Holdings reported a robust Q3 2025, marked by a 76% growth in applications year-to-date and 47% growth in Q3 alone, fueling a 30% expansion in its total customer base. This accelerated top-of...
- Katapult grew total applications by 76% in the first nine months of 2025, with an 80% increase in Q3 alone, indicating strong top-of-funnel activity.
- The total customer base expanded over 30% in Q3, fueled by a near 47% growth in unique new customers, marking four consecutive quarters of accelerating customer growth.
- Monthly active users of the Katapult app increased nearly 49% year-over-year in Q3, reflecting enhanced consumer engagement and app-driven marketplace growth.
- +11 more takeaways
Yatra Fiscal Q2 2026 Earnings Call - Surge in Revenue and Profitability Driven by Corporate Travel Expansion
Yatra reported a standout second quarter in fiscal 2026, with revenues climbing nearly 50% year over year to $39.5 million and profits turning positive to $1.1 million from a previous loss. This perfo...
- Yatra’s Q2 fiscal 2026 revenue grew 48.5% year over year to INR 3,508 million ($39.5 million).
- Adjusted EBITDA surged 218% year over year to INR 212 million ($2.4 million).
- Profit after tax increased to INR 98.8 million ($1.1 million) versus a loss in prior year period.
- +9 more takeaways
BitFuFu Q3 2025 Earnings Call - Cloud Mining Demand Surges Amid Strategic Expansion and Market Resilience
BitFuFu's third quarter 2025 results illustrate a decisive inflection point. Total revenue doubled year over year to $180.7 million, driven primarily by a 78% jump in cloud mining revenue to $123 mill...
- Total revenue reached $180.7 million in Q3 2025, doubling year-over-year and growing 57% sequentially.
- Cloud mining revenue hit $123 million, a 78.4% year-over-year increase, accounting for 68% of total revenue.
- Adjusted EBITDA rose to $22.1 million, up substantially from $5.8 million the prior year.
- +12 more takeaways
Rockwell Medical 3Q 2025 Earnings Call - Navigating Major Customer Transition While Driving Profitability and Growth
Rockwell Medical's third quarter of 2025 was marked by a major customer exit that impacted top-line sales but reinforced the company’s resilience and strategic repositioning. Despite a 44% year-over-y...
- Rockwell Medical's largest customer transition caused a 44% sales decline in Q3 2025 compared to prior year, with net sales at $15.9 million.
- Despite sales pressures, the company achieved positive adjusted EBITDA of $50,000 in Q3 2025, improving sequentially from negative adjustments earlier in the year.
- More than 80% of Rockwell’s customers now operate under multi-year contracts, enhancing revenue stability and reducing customer concentration risks.
- +9 more takeaways
Local Bounti Q3 2025 Earnings Call - Operational Scale-Up and Market Validation Mark Inflection Point
Local Bounti’s third quarter results reveal a pivotal phase where operational execution meets a broader market shift validating controlled environment agriculture (CEA) as permanent retail infrastruct...
- Local Bounti achieved 19% year-over-year revenue growth in Q3 2025, reaching $12.2 million revenue.
- Texas facility completed transition and reached full harvest capacity in early August, doubling output.
- Automated harvesting system in Texas increased labor productivity by ~19% and reduced labor costs per pound by ~17%.
- +11 more takeaways
Dingdong Limited Q3 2025 Earnings Call - Sustained Profitability and Strategic Shift to Product-Led Growth
Dingdong Limited reported its highest-ever quarterly GMV and revenue in Q3 2025, with RMB 7.27 billion and RMB 6.66 billion respectively, marking seven consecutive quarters of year-over-year revenue g...
- Dingdong achieved its highest-ever quarterly GMV (RMB 7.27 billion) and revenue (RMB 6.66 billion) in Q3 2025 with slight year-over-year growth.
- The company maintained profitability for 12 consecutive quarters under non-GAAP and 7 quarters under GAAP, with non-GAAP net profit margin at 1.5%.
- The 4G strategy (good users, goods, service, mindset) improved product quality, user retention, and order frequency; good product SKUs comprised 37.2% of SKUs contributing 44.7% of GMV in September.
- +7 more takeaways